Willkommen, schön sind Sie da!
Logo Ex Libris

Tumor Metabolome Targeting and Drug Development

  • Kartonierter Einband
  • 208 Seiten
(0) Erste Bewertung abgeben
Bewertungen
(0)
(0)
(0)
(0)
(0)
Alle Bewertungen ansehen
In this volume, the major metabolic alterations identified in cancer and tumor-associated cells are explored, including discussion... Weiterlesen
20%
192.00 CHF 153.60
Print on Demand - Auslieferung erfolgt in der Regel innert 4 bis 6 Wochen.
Bestellung & Lieferung in eine Filiale möglich

Beschreibung

In this volume, the major metabolic alterations identified in cancer and tumor-associated cells are explored, including discussions of former and emerging approaches to drug development in targeting cancer cell metabolism.

The metabolic network in cells promotes the generation of both energy and biomass needed for them to grow, divide and differentiate. However, the metabolism of malignant cells generally varies from that of normal cells. These differences provide a platform for the discovery of new approaches to targeting potential vulnerabilities in cancer cells for therapeutic options Some of the significant changes that occur involve ATP production and consumption that modulates the ATP to ADP ratio, hypoxia and the effects of reactive oxygen species on glycolysis, regulation of mitochondrial respiration, induction and suppression of autophagy, and the Warburg effect and reverse Warburg effect--these topics and more are discussed in this volume.



Provides expert reviews of multiple metabolic targets covering the glycolytic pathway, Krebs cycle, tumor microenvironment, hypoxia, and therapeutic strategies

Explores experimental models for evaluating the tumor metabolome to provide knowledge and access to the field

Bridges the fields of cancer cell metabolism, tumor/stroma microenvironments, autophagy, drug discovery and development, and translational application of novel cancer therapies



Autorentext
Dr. Steven B. Kanner is the Vice President of Discovery Biology at Astex Pharmaceuticals. He has been a pharmaceutical research leader with over 20 years of extensive experience in novel target identification and validation, assay development, both small molecule and antibody drug discovery, and expertise in oncology, immunology and inflammation. For more detail, please see the attached CV herewith.

Inhalt
Chapter 1: Tumor cell metabolic reprogramming and drug targeting (Steven B. Kanner)
Chapter 2: Cancer metabolism: a nexus of matter, energy and reactive oxygen species (Paul M. Bingham, Shawn D. Stuart, Zuzana Zachar) Chapter 3: Regulating mitochondrial respiration in cancer (Teresa L. Serafim and Paulo J. Oliveira)
Chapter 4: Regulation of cancer cell metabolism by hypoxia (Ashleigh Pulkoski-Gross, Nikki A. Evensen and Jian Cao)
Chapter 5: Glucose metabolism and the anti-oxidative defence system in cancer cells: Options for application of ROS-based anticancer drugs (Gernot Bruchelt, Rupert Handgretinger, Mirjam Weckenmann, Talia Hahn)
Chapter 6: Modulating autophagy and the reverse Warburg effect (Maria Vaccaro, Claudio D. Gonzalez, Silvia Alvarez and Alejandro Ropolo)
Chapter 7: Metabolic adaptation in reprogrammed cancer cells (Kevin Marks and Charles Kung)
Chapter 8: Targeting of PFKFB3 (Katarina Färnegårdh, Maria Shoshan, Lars Ährlund-Richter)

Produktinformationen

Titel: Tumor Metabolome Targeting and Drug Development
Editor:
EAN: 9781493953431
ISBN: 1493953435
Format: Kartonierter Einband
Herausgeber: Springer New York
Genre: Medizin
Anzahl Seiten: 208
Gewicht: 324g
Größe: H235mm x B155mm x T11mm
Jahr: 2016
Auflage: Softcover reprint of the original 1st ed. 2014